ASN007 (benzenesulfonate)

ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of ERK. ASN007 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 benzenesulfonate exhibits significant anti proliferative activity against various tumor cells. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations[1][2].

Product Specifications

CAS Number

[2055597-39-0]

Product Name Alternative

ERK-IN-3 (benzenesulfonate)

UNSPSC

12352005

Target

ERK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/erk-in-3-benzenesulfonate.html

Purity

99.72

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN.O=S(C5=CC=CC=C5)(O)=O

Molecular Formula

C28H31ClFN7O5S

Molecular Weight

632.11

References & Citations

[1]Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17 (1) .|[2]Portelinha A, et al. ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell Rep Med. 2021 Jul 21;2 (7) :100350.